背景:腹主动脉瘤(AAA)是一个节段,进步,和致命的血管疾病,目前小型AAAs的策略是单独密切观察。这项研究的目的是总结可用的证据,以评估抗生素对小型腹主动脉瘤(AAA)的影响。
方法:我们搜索了PubMed,EMBASE,WebofScience,和Scopus从开始到2023年9月29日,包括随机对照试验(RCT),评估抗生素对人类小AAAs的影响。我们首先进行了荟萃分析,以评估抗生素对小AAAs的影响。之后,应用网络药理学分析来研究根据荟萃分析结果产生的最佳药物.我们搜索了Pharmmapper和GeneCards,以获得所选药物的共同潜在靶标和AAA相关靶标。通过STRING数据库进行蛋白质-蛋白质相互作用网络和功能富集分析,Cytoscape3.7.2软件,R,分别。进行对接研究以进行验证。
结果:我们纳入了6个RCT的数据,共997例患者。该荟萃分析的结果表明,罗红霉素在减缓AAA扩张速率方面表现出适度但统计学上显著的保护作用。此外,我们随后的生物信息学分析确定了MMP-2、MMP-9、ALB、MMP-3和CCL-5作为潜在的治疗靶点,可以探索使用罗红霉素治疗AAA。
结论:结论:该研究表明罗红霉素是一种治疗小型AAAs的有前途的药物,并支持其在小型AAAs中的潜在临床应用。
BACKGROUND: Abdominal aortic aneurysm (AAA) is a segmental, progressive, and fatal vascular disorder, and the current strategy for small AAAs is close observation alone.The purpose of this study is to summarize the available evidence to assess the effects of antibiotics on small abdominal aortic aneurysms (AAA).
METHODS: We searched PubMed, EMBASE, Web of Science, and Scopus from inception to September 29, 2023, and included randomized controlled trials (RCTs) that evaluated the effects of antibiotics on small AAAs in humans. We first performed a meta-analysis to assess the effects of antibiotics on small AAAs. Afterward, network pharmacology analysis was applied to investigate the optimal drug generated from the meta-analysis results. We searched Pharmmapper and GeneCards to obtain the common potential targets of the selected drug and AAA-related targets. The protein-protein interaction network and functional enrichment analysis were performed by the STRING database, Cytoscape 3.7.2 software, and R, respectively. Docking studies were carried out for validation.
RESULTS: We incorporated data from six RCTs involving a total of 997 patients. The results of this meta-analysis revealed that
roxithromycin exhibited a modest yet statistically significant protective effect in terms of slowing down the AAA expansion rate. Furthermore, our subsequent bioinformatics analysis pinpointed MMP-2, MMP-9, ALB, MMP-3, and CCL-5 as potential therapeutic targets that could be explored for the treatment of AAA using
roxithromycin.
CONCLUSIONS: In conclusion, the study indicates
roxithromycin is a promising drug for treating small AAAs and supports its underlying clinical use in small AAAs.